1.Clinical observation on treatment of primary hepatocarcinoma patients with continuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules and small dose TACE
Xiaohong YU ; Jibin LOU ; Jixi YAN ; Aixia DING
Chongqing Medicine 2015;(24):3367-3369
Objective To evaluate the efficacy and adverse reaction of continuous low-dose oral Tegafur,Gimeracil and Oter-acil Potassium Capsules in combination with small dose of transcatheter arterial chemoembolization(TACE)in the treatment of pri-mary hepatocarcinoma patients.Methods A total of 92 primary hepatocarcinoma patients who were unable or unwilling to surgery. Patients were divided into treatment group and control group,with each consisted of 46 cases.The treatment group was given con-tinuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules in combination with small dose of TACE,and the control group was given small dose TACE.All study subjects were reviewed DSA and CT.tumor angiogenesis and tumor staining,Karnof-sky Performance Scores(KPS),postoperative adverse events and complications was evaluated.PFS and the survival rate of three months,six months,one year and two years was estimated.Results Tumor angiogenesis and staining were significantly lower in treatment group than those of the control group(P <0.05).Patients in the two groups had the same rates of side effects and com-plications(P >0.05).KPS scores in the two groups had no significant difference before and after treatment(P >0.05 ).PFS,one year and two years survival rate were better in treatment group than in the control group(P <0.05).Conclusion Combined appli-cation of continuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules and small dose TACE was significantly su-perior to TACE alone in the treatment of primary hepatocarcinoma patients.
2.Esophageal stent covered with radioactive 125I seeds arranged at different distance:dosimetric ;comparison study
Huimin YU ; Hongtao ZHANG ; Baiying DING ; Aixia SUI ; Juan WANG ; Juan WU
Journal of Interventional Radiology 2015;(4):338-341
Objective To study the dose distribution in tumor target of radioactive esophageal stent covered with 125I seeds which are arranged at different distance. Methods According to the longitudinal and horizontal distance between the 125I seeds, the experiment was divided into group A (0.5 cm), group B (1.0 cm) and group C (1.5 cm). A sheet of white paper, on which a 2cm diameter circle was drawn and was marked with a 5 cm scale, was scanned with a laser scanner, and the scanning data were saved in JPEG format on the computer desktop. By using image conversion program, pictures of 17 layers with the layer space of 5 mm were created. The picture was transmitted to the computer treatment planning system (TPS) to simulate a 2 cm diameter and 8 cm length esophageal stent. Using TPS to delineate the tumor target area (gross tumor volume, GTV), which was used as the simulation of the inner boundary of the tumor target area, outward expansion of 0.5 cm being regarded as the outside border. An annular and 6cm length tube was delineated and it was used as the target area, and the same prescription dose was set, and in each group 125I seeds of 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 0.9 mCi were successively loaded on the simulation of esophageal stent. With the help of TPS the DVH graph was obtained, and the D90 (the dose received by 90% of the target) and V90 (the percentage of the GTV receiving 90% the prescription dose) of the three groups were determined. The results were statistically analyzed. Results The arithmetic mean values of D90 of group A, B and C were (217.15± 19.92), (89.16±32.44) and (31.68±11.52) Gy respectively (F=159.18, P<0.05); and the arithmetic mean values of V90 of group A, B and C were (100.00±0.00)%, (86.47±21.36)%and (29.33±21.54)%respectively (F=32.11, P<0.05). Conclusion The 2 cm-diameter radioactive esophageal stent covered with 125I seeds, which have o.6mci activity and are arranged at 1.0cm distance in both longitudinal and horizontal directions, should be recommended in clinical practice.